Reported about 1 month ago
Sanofi exceeded market expectations with a 14.4% increase in third-quarter earnings, reaching 4.6 billion euros, thanks to an earlier-than-expected start to vaccination season. Vaccine sales climbed 25.5% to 3.8 billion euros. The company's plans for a significant stake sale in its consumer unit aim to fund next-generation drug trials. Analysts forecast further growth for Sanofi’s shares following these impressive results, aided by strong performance from its top-selling drug Dupixent.
Source: YAHOO